These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16475914)

  • 21. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
    Lipton A; Cook RJ; Coleman RE; Smith MR; Major P; Terpos E; Berenson JR
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):346-53. PubMed ID: 17562244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
    Radom S; Zulawski M; Golebiowska D
    Pol Med J; 1972; 11(4):809-14. PubMed ID: 4342776
    [No Abstract]   [Full Text] [Related]  

  • 23. The Role of Matrix Metalloproteinase-9 (MMP-9) as a Prognostic Factor in Epithelial and Lymphatic Neoplasia.
    Pârvănescu V; Georgescu M; Georgescu I; Șurlin V; Pătraşcu Ș; Picleanu AM; Georgescu E
    Chirurgia (Bucur); 2015; 110(6):506-10. PubMed ID: 26713823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
    Dimopoulos MA; Moulopoulos A; Delasalle K; Alexanian R
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):359-69. PubMed ID: 1582978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lambda type microglobulinic myeloma].
    Guillermo Fongi E; Rascosky S; Cooperberg L; Sánchez de la Vega W
    Rev Clin Esp; 1972 Feb; 124(3):303-6. PubMed ID: 5023371
    [No Abstract]   [Full Text] [Related]  

  • 26. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.
    Zdzisińska B; Walter-Croneck A; Kandefer-Szerszeń M
    Leuk Res; 2008 Nov; 32(11):1763-9. PubMed ID: 18472160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Int J Cancer; 2005 Sep; 116(3):422-7. PubMed ID: 15818624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What does a monoclonal component signify?].
    Skrede S; Stavem P
    Tidsskr Nor Laegeforen; 1973 Sep; 93(25):1788-9. PubMed ID: 4771915
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
    Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plasmocytoma of throid cartilage in Kahler's disease].
    Debain JJ; Poulain H; Peytral C; Meyer B
    Ann Otolaryngol Chir Cervicofac; 1974; 91(7-8):429. PubMed ID: 4451331
    [No Abstract]   [Full Text] [Related]  

  • 32. Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease.
    Wang PH; Tsai HT; Tee YT; Lin LY; Yang SF; Hsieh YS
    Fertil Steril; 2009 Nov; 92(5):1679-84. PubMed ID: 18937938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A further case of nonexcreting myeloma].
    Klepping C; Destaing F; Duzer A; Villand J; Carli PM; Seigneuric C
    Lyon Med; 1972 Sep; 228(14):131-6. PubMed ID: 5082764
    [No Abstract]   [Full Text] [Related]  

  • 34. [Electrophoretic studies of the serum of rats bearing Oberling's aleukemic myeloma transplanted into the tibia].
    Magrassi B; Raimondi L; Roveta G
    Arch Sci Med (Torino); 1967 Feb; 123(2):63-70. PubMed ID: 6057363
    [No Abstract]   [Full Text] [Related]  

  • 35. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
    Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
    Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Atypical myeloma].
    Matysová A; Vachtenheim J
    Vnitr Lek; 1976 Feb; 22(2):179-83. PubMed ID: 1258406
    [No Abstract]   [Full Text] [Related]  

  • 37. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A further case of myeloma with nonexcreting plasmocytes].
    Fabia F; Burnichon J; Cornillot P
    Nouv Presse Med; 1972 Oct; 1(37):2480. PubMed ID: 5084536
    [No Abstract]   [Full Text] [Related]  

  • 40. Skeletal abnormalities in multiple myeloma.
    Mulligan ME
    Radiology; 2005 Jan; 234(1):313-4; author reply 314. PubMed ID: 15618390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.